Credit Suisse AG cut its position in Cambrex Corporation (NYSE:CBM) by 19.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 103,423 shares of the biotechnology company’s stock after selling 25,442 shares during the period. Credit Suisse AG owned 0.32% of Cambrex Corporation worth $5,693,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in CBM. Flinton Capital Management LLC boosted its position in Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock worth $103,000 after buying an additional 68 shares in the last quarter. YorkBridge Wealth Partners LLC boosted its position in Cambrex Corporation by 20.2% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,874 shares of the biotechnology company’s stock worth $106,000 after buying an additional 315 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in Cambrex Corporation during the first quarter worth approximately $109,000. Dubuque Bank & Trust Co. purchased a new position in Cambrex Corporation during the first quarter worth approximately $144,000. Finally, Ameritas Investment Partners Inc. purchased a new position in Cambrex Corporation during the first quarter worth approximately $151,000. 98.28% of the stock is owned by hedge funds and other institutional investors.
Shares of Cambrex Corporation (NYSE CBM) opened at 54.90 on Wednesday. The stock has a market capitalization of $1.79 billion, a PE ratio of 20.90 and a beta of 2.28. The firm has a 50-day moving average of $59.25 and a 200 day moving average of $55.49. Cambrex Corporation has a 52-week low of $38.30 and a 52-week high of $62.95.
Cambrex Corporation (NYSE:CBM) last released its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.76. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. The firm had revenue of $134.55 million during the quarter, compared to analysts’ expectations of $136.82 million. During the same period last year, the business earned $0.68 earnings per share. Cambrex Corporation’s revenue was up 13.4% compared to the same quarter last year. Equities research analysts forecast that Cambrex Corporation will post $3.08 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Cambrex Corporation (CBM) Shares Sold by Credit Suisse AG” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2017/08/09/credit-suisse-ag-lowers-stake-in-cambrex-corporation-cbm-updated-updated.html.
CBM has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of Cambrex Corporation from a “hold” rating to a “buy” rating and set a $59.00 price target for the company in a research note on Thursday, May 11th. BidaskClub raised shares of Cambrex Corporation from a “hold” rating to a “buy” rating in a research note on Friday, August 4th. Finally, ValuEngine cut shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $64.00.
In other Cambrex Corporation news, Director Leon J. Hendrix, Jr. sold 20,656 shares of the stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $55.95, for a total transaction of $1,155,703.20. Following the completion of the transaction, the director now owns 74,662 shares of the company’s stock, valued at $4,177,338.90. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Steven M. Klosk sold 12,000 shares of the stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $54.19, for a total transaction of $650,280.00. Following the transaction, the chief executive officer now directly owns 95,328 shares of the company’s stock, valued at approximately $5,165,824.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 70,656 shares of company stock valued at $4,064,423. 2.48% of the stock is owned by company insiders.
About Cambrex Corporation
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
